AT

Alterity Therapeutics

www.alteritytherapeutics.com link_icon

Company Market Research Report: Alterity Therapeutics



Company Overview



Name and Mission


  • Name: Alterity Therapeutics

  • Mission: To create an alternate, healthier future for people with neurodegenerative diseases by disrupting the trajectory these diseases typically follow.


Foundation and Founders


  • Founded: 1997

  • Founders: Geoffrey Kempler


Key People


  • Chief Executive Officer: David Stamler, M.D.

  • Vice President, Research and Nonclinical Development: Margaret Bradbury, Ph.D.

  • Board of Directors:

  • Geoffrey Kempler, Chairman & Founder

  • Lawrence Gozlan, Non-Executive Director

  • Peter Marks, Non-Executive Director

  • Brian Meltzer, Non-Executive Director


Headquarters


  • Locations: Melbourne, Australia, and San Francisco, USA


Number of Employees


  • No information is available.


Revenue


  • No information is available.


Known For


  • Developing first-in-class therapies to treat neurodegenerative diseases, particularly focusing on Parkinsonian disorders and Multiple System Atrophy (MSA).


Products



Overview


  • Lead Candidate: ATH434


High-Level Description


  • ATH434: An oral agent designed to inhibit the aggregation of pathological proteins, particularly α-synuclein, implicated in neurodegenerative diseases.


Key Features


  • Redistribute: Binds excess iron within the brain and redistributes it safely without depleting essential iron needed for bodily functions.

  • Reduce: Reduces α-synuclein aggregation and oxidative stress by managing iron levels.

  • Rescue: Protects neurons from future damage by limiting neurodegeneration.


Recent Developments



Clinical Trials and Studies


  • ATH434-201 Phase 2 Trial: Randomized, double-blind, placebo-controlled trial focusing on early-stage MSA. The trial uses biomarkers and wearable sensors to track motor activities.

  • ATH434-202 Phase 2 Trial: Open-label study on advanced MSA patients, focusing on neuroimaging and protein biomarkers to evaluate drug efficacy and safety.

  • bioMUSE Natural History Study: Tracks the progression of MSA patients to gather data for optimizing future trials.


Recent Announcements


  • July 2024: Positive interim data from ATH434-202 Phase 2 clinical trial, demonstrating improvements in UMSARS Activities of Daily Living Scale and neurological symptoms in some patients.

  • April 2024: Data presentations at the American Academy of Neurology (AAN) Annual Meeting and World Orphan Drug Congress highlighting new characteristics of ATH434 and its potential for treating Friedreich’s Ataxia.

  • May 2024: Introduction of novel MRI technology and machine learning in the bioMUSE study to analyze brain iron and volume changes in MSA patients.


New Partnerships and Collaborations


  • Collaboration with Vanderbilt University Medical Center for the bioMUSE study.

  • Nonclinical studies with the Florey Institute of Neuroscience and Vanderbilt University Medical Center for evaluating ATH434 in Parkinson’s Disease.


Financial Highlights


  • Quarter Ending 30 June 2024: Operating cash outflows of A$5.6M with a cash balance of A$12.6M.


Orphan Drug Designation


  • ATH434: Granted Orphan Drug designation by the U.S. FDA and the European Commission, providing market exclusivity and development incentives.


Conclusion


Alterity Therapeutics demonstrates a strong commitment to developing therapies for neurodegenerative diseases through innovative trials, partnerships, and active progress in significant clinical studies. The company's ongoing advancements in the clinical and scientific fields support its mission to create an alternate future for those living with debilitating diseases.